Jeff Yass’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $311M | Sell |
4,437,400
-1,049,900
| -19% | -$54.3M | 0.02% | 437 |
|
|
2026
Q1 | $279M | Sell |
5,487,300
-52,500
| -0.9% | -$2.45M | 0.03% | 409 |
|
|
2025
Q4 | $163M | Sell |
5,539,800
-1,553,700
| -22% | -$42.2M | 0.02% | 622 |
|
|
2025
Q3 | $183M | Buy |
7,093,500
+784,100
| +12% | +$21.9M | 0.02% | 576 |
|
|
2025
Q2 | $174M | Buy |
6,309,400
+1,232,900
| +24% | +$32.5M | 0.02% | 500 |
|
|
2025
Q1 | $144M | Sell |
5,076,500
-596,100
| -11% | -$21.2M | 0.02% | 503 |
|
|
2024
Q4 | $236M | Buy |
5,672,600
+1,864,800
| +49% | +$89.1M | 0.04% | 371 |
|
|
2024
Q3 | $254M | Buy |
3,807,800
+1,175,400
| +45% | +$108M | 0.04% | 328 |
|
|
2024
Q2 | $313M | Buy |
2,632,400
+672,400
| +34% | +$85.1M | 0.06% | 248 |
|
|
2024
Q1 | $209M | Sell |
1,960,000
-339,000
| -15% | -$34.2M | 0.04% | 392 |
|
|
2023
Q4 | $229M | Sell |
2,299,000
-187,400
| -8% | -$15.8M | 0.04% | 344 |
|
|
2023
Q3 | $257M | Sell |
2,486,400
-46,000
| -2% | -$5.13M | 0.05% | 276 |
|
|
2023
Q2 | $308M | Buy |
2,532,400
+173,000
| +7% | +$23.1M | 0.06% | 236 |
|
|
2023
Q1 | $362M | Sell |
2,359,400
-488,500
| -17% | -$80.6M | 0.08% | 202 |
|
|
2022
Q4 | $512M | Buy |
2,847,900
+535,900
| +23% | +$87.6M | 0.13% | 114 |
|
|
2022
Q3 | $273M | Sell |
2,312,000
-12,300
| -0.5% | -$1.87M | 0.07% | 212 |
|
|
2022
Q2 | $332M | Sell |
2,324,300
-1,564,200
| -40% | -$224M | 0.08% | 179 |
|
|
2022
Q1 | $670M | Sell |
3,888,500
-1,225,800
| -24% | -$206M | 0.12% | 122 |
|
|
2021
Q4 | $1.3B | Sell |
5,114,300
-1,367,500
| -21% | -$400M | 0.19% | 72 |
|
|
2021
Q3 | $2.49B | Buy |
6,481,800
+1,980,700
| +44% | +$730M | 0.33% | 36 |
|
|
2021
Q2 | $1.06B | Sell |
4,501,100
-1,355,000
| -23% | -$242M | 0.15% | 96 |
|
|
2021
Q1 | $767M | Buy |
5,856,100
+673,200
| +13% | +$97.6M | 0.12% | 128 |
|
|
2020
Q4 | $541M | Buy |
5,182,900
+2,526,300
| +95% | +$256M | 0.09% | 173 |
|
|
2020
Q3 | $188M | Buy |
2,656,600
+813,800
| +44% | +$56.7M | 0.04% | 356 |
|
|
2020
Q2 | $118M | Buy |
1,842,800
+1,061,100
| +136% | +$58.1M | 0.03% | 450 |
|
|
2020
Q1 | $23.4M | Buy |
781,700
+560,000
| +253% | +$12.9M | 0.01% | 1081 |
|
|
2019
Q4 | $4.34M | Sell |
221,700
-22,500
| -9% | -$399K | ﹤0.01% | 3179 |
|
|
2019
Q3 | $3.89M | Buy |
244,200
+18,700
| +8% | +$276K | ﹤0.01% | 3088 |
|
|
2019
Q2 | $3.3M | Buy |
225,500
+88,700
| +65% | +$1.91M | ﹤0.01% | 3301 |
|
|
2019
Q1 | $2.78M | Buy |
+136,800
| New | +$2.54M | ﹤0.01% | 3242 |
|
Other funds holding MRNA
TP
Jeff Yass's MRNA Position: Q2 2026 in Review
Jeff Yass increased its Moderna (MRNA) stake by 552% in Q2 2026, buying an estimated $15.7M and bringing the position to 357,774 shares worth $25.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2212.
Jeff Yass first reported a position in MRNA in Q4 2018 and has held it in 29 quarters since. The position peaked at $270M in Q3 2021. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- Jeff Yass held 357,774 shares of Moderna worth $25.1M as of Q2 2026.
- Jeff Yass bought 302,934 Moderna shares in Q2 2026, an estimated $15.7M.
- Moderna made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #2212 holding.
- Jeff Yass first reported a position in Moderna in Q4 2018 and has held it in 29 quarters since.
- Jeff Yass's Moderna position peaked at $270M in Q3 2021.
- 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.